Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 醫學系
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/535209
Title: Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection
Authors: Tsai W.-C.
Hsu W.-T.
WANG-DA LIU 
HSIN-YUN SUN 
YU-CHUNG CHUANG 
YU-SHAN HUANG 
ARISTINE CHENG 
KUAN-YIN LIN 
YI-CHIA HUANG 
Chen G.-J.
Huang S.-H.
WANG-HUEI SHENG 
SZU-MIN HSIEH 
CHIEN-CHING HUNG 
SHAN-CHWEN CHANG 
Issue Date: 2019
Publisher: Blackwell Publishing Ltd
Journal Volume: 39
Journal Issue: 8
Start page/Pages: 1408-1417
Source: Liver International
Abstract: 
Background: Tenofovir disoproxil fumarate (TDF) is active against both HBV and HIV. Whether the introduction of TDF-containing combination antiretroviral therapy (cART) has improved the outcome of HIV/HBV-coinfected patients remains unclear in areas of higher HBV endemicity. Methods: We retrospectively reviewed medical records of newly diagnosed antiretroviral-na?ve HIV-infected patients between 2007 and 2015. Four groups of patients were defined, according to the HBV status and availability of TDF for HIV treatment in Taiwan in 2011. The primary outcome was all-cause mortality. Results: During the 9-year study period, 1,723 HIV-infected patients were included, with a median age of 31?years and baseline CD4 count of 273 cells per μL. The HBV seroprevalence had declined from 18.1% (125/692) in the pre-TDF era to 10.1% (104/1031) in the post-TDF era. The respective mortality rate for HIV/HBV-coinfected and HIV-monoinfected patients in the pre-TDF era was 23.2 (95% CI, 12.5-43.1) and 9.6 (95% CI, 6.1-15.0) deaths per 1000 person-years of follow-up [PYFU], and the respective mortality rate in the post-TDF era was 15.7 (95% CI, 7.0-34.8) and 8.0 (95% CI, 5.5-11.6) deaths per 1000 PYFU. The adjusted hazard ratio for mortality in multivariate Cox proportional-hazards regression analysis among HIV/HBV-coinfected patients compared to HIV-monoinfected patients was 2.79 (95% CI, 1.25-6.22) in pre-TDF era and 1.11 (95% CI, 0.45-2.72) in post-TDF era. Conclusions: In this country of high HBV endemicity, the adverse impact of chronic HBV infection on the survival observed in the pre-TDF era has significantly diminished among HIV/HBV-coinfected patients compared to HIV-monoinfected patients in the era of TDF-containing cART. ? 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061927387&doi=10.1111%2fliv.14059&partnerID=40&md5=48034fefe4fa5af002126dd8e46cd414
https://scholars.lib.ntu.edu.tw/handle/123456789/535209
ISSN: 1478-3223
DOI: 10.1111/liv.14059
SDG/Keyword: tenofovir disoproxil; 9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine; adenine; antiretrovirus agent; phosphorous acid; adult; all cause mortality; CD4 lymphocyte count; controlled study; female; follow up; health care availability; hepatitis B; Hepatitis B virus; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; major clinical study; male; medical record review; mixed infection; mortality; mortality rate; retrospective study; Review; seroprevalence; survival; Taiwan; complication; epidemiology; hepatitis B; Human immunodeficiency virus infection; mixed infection; virology; Adenine; Adult; Anti-Retroviral Agents; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Male; Phosphorous Acids; Retrospective Studies; Taiwan
[SDGs]SDG3
Appears in Collections:醫學系

Show full item record

SCOPUSTM   
Citations

9
checked on Mar 27, 2023

WEB OF SCIENCETM
Citations

8
checked on Mar 5, 2023

Page view(s)

32
checked on Mar 24, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback